168 related articles for article (PubMed ID: 24570811)
1. Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.
Chang JH; Kim CY; Choi BS; Kim YJ; Kim JS; Kim IA
J Korean Neurosurg Soc; 2014 Jan; 55(1):5-11. PubMed ID: 24570811
[TBL] [Abstract][Full Text] [Related]
2. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.
Mohammadi H; Shiue K; Grass GD; Verma V; Engellandt K; Daubner D; Schackert G; Gondim MJ; Gondim D; Vortmeyer AO; Kamer AP; Jin W; Robinson TJ; Watson G; Yu HM; Lautenschlaeger T
Neurooncol Pract; 2020 Mar; 7(2):185-195. PubMed ID: 32626587
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53.
Kang HC; Kim CY; Han JH; Choe GY; Kim JH; Kim JH; Kim IA
J Neurooncol; 2011 Mar; 102(1):157-62. PubMed ID: 20632071
[TBL] [Abstract][Full Text] [Related]
5. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.
Sanghera P; Perry J; Sahgal A; Symons S; Aviv R; Morrison M; Lam K; Davey P; Tsao MN
Can J Neurol Sci; 2010 Jan; 37(1):36-42. PubMed ID: 20169771
[TBL] [Abstract][Full Text] [Related]
6. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations.
Chaskis C; Neyns B; Michotte A; De Ridder M; Everaert H
Surg Neurol; 2009 Oct; 72(4):423-8. PubMed ID: 19150114
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression: relevance with respect to treatment of high-grade gliomas.
Fink J; Born D; Chamberlain MC
Curr Treat Options Oncol; 2011 Sep; 12(3):240-52. PubMed ID: 21594589
[TBL] [Abstract][Full Text] [Related]
8. Early post-treatment pseudo-progression amongst glioblastoma multiforme patients treated with radiotherapy and temozolomide: a retrospective analysis.
Gunjur A; Lau E; Taouk Y; Ryan G
J Med Imaging Radiat Oncol; 2011 Dec; 55(6):603-10. PubMed ID: 22141608
[TBL] [Abstract][Full Text] [Related]
9. Pseudoprogression Is Frequent After Front-Line Radiation Therapy in Pediatric Low-Grade Glioma: Results From the German Low-Grade Glioma Cohort.
Stock A; Hancken CV; Kandels D; Kortmann RD; Dietzsch S; Timmermann B; Pietsch T; Bison B; Schmidt R; Pham M; Gnekow AK; Warmuth-Metz M
Int J Radiat Oncol Biol Phys; 2022 Apr; 112(5):1190-1202. PubMed ID: 34933039
[TBL] [Abstract][Full Text] [Related]
10. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.
van West SE; de Bruin HG; van de Langerijt B; Swaak-Kragten AT; van den Bent MJ; Taal W
Neuro Oncol; 2017 May; 19(5):719-725. PubMed ID: 28453748
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas.
Huang Y; Ding H; Wu Q; Li Z; Li H; Li S; Xie C; Zhong Y
Cancer Manag Res; 2019; 11():6003-6009. PubMed ID: 31303796
[TBL] [Abstract][Full Text] [Related]
12. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.
Tsien C; Galbán CJ; Chenevert TL; Johnson TD; Hamstra DA; Sundgren PC; Junck L; Meyer CR; Rehemtulla A; Lawrence T; Ross BD
J Clin Oncol; 2010 May; 28(13):2293-9. PubMed ID: 20368564
[TBL] [Abstract][Full Text] [Related]
13. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
14. Pseudoprogression in high-grade glioma.
Knudsen-Baas KM; Moen G; Fluge Ø; Storstein A
Acta Neurol Scand Suppl; 2013; (196):31-7. PubMed ID: 23190289
[TBL] [Abstract][Full Text] [Related]
15. Population-based study of pseudoprogression after chemoradiotherapy in GBM.
Roldán GB; Scott JN; McIntyre JB; Dharmawardene M; de Robles PA; Magliocco AM; Yan ES; Parney IF; Forsyth PA; Cairncross JG; Hamilton MG; Easaw JC
Can J Neurol Sci; 2009 Sep; 36(5):617-22. PubMed ID: 19831132
[TBL] [Abstract][Full Text] [Related]
16. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
Gerstner ER; McNamara MB; Norden AD; Lafrankie D; Wen PY
J Neurooncol; 2009 Aug; 94(1):97-101. PubMed ID: 19221865
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
18. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
19. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
[TBL] [Abstract][Full Text] [Related]
20. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
